Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Takhzyro (lanadelumab-flyo) for the Prevention of Hereditary Angioedema

HAE causes irregulation in plasma kallikrein activity due to deficient or dysfunctional C1 inhibitor. Image courtesy of Emw.

  • Takhzyro
  • Takhzyro
  • Takhzyro

Go Top